81167-60-4

Usage

Uses

Used in Pharmaceutical Industry:
4-tert-butyl-2-chloropyridine is used as a key building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-tert-butyl-2-chloropyridine is employed as a crucial intermediate in the production of agrochemicals, aiding in the creation of effective pest control agents and other agricultural products.
Used in Organic Materials Synthesis:
4-tert-butyl-2-chloropyridine is utilized as a component in the synthesis of organic materials, playing a role in the development of advanced materials with specific properties for various applications.
Used in Specialty Chemicals Production:
As an intermediate in the production of specialty chemicals, 4-tert-butyl-2-chloropyridine is instrumental in the manufacturing process, enabling the creation of unique chemical compounds with specialized uses.
It is important to handle and use 4-tert-butyl-2-chloropyridine with appropriate safety precautions due to its potential hazards, ensuring the safe and effective application of this versatile chemical compound in various industries.

Upstream product

• 109-09-1 2-chloropyridine 
• 38442-51-2 tert-butylmercury chloride 
• 23569-17-7 4-tert-butylpyridine N-oxide 
• 3978-81-2 4-tert-butylpyridine 

Downstream Products

• 1350449-24-9 C₄₁H₆₁NO₄ 
• 1350449-25-0 4-tert-butylpyridine-2,6-bis[2-(4,6-di-tert-butylphenol)] 
• 50488-34-1 4-(tert-butyl)-2-bromopyridine 
• 583052-24-8 2-(2',4'-difluorophenyl)-4-tert-butyl-pyridine 
• 53911-36-7 4-(tert-butyl)-2-phenylpyridine 
• 2050-23-9 diethyl suberate 
• 72914-19-3 4,4'-di-tert-butyl-2,2'-bipyridine 

Relevant academic research and scientific papers

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Organometallic complex and Organic light emitting diode comprising the same

An organometallic complex and an organic light emitting device including the same are disclosed. (by machine translation)

A preparation method of 4-tert-butyl-2-chloropyridine and 4-tert-butyl-2,6-dichloro-pyridine

The invention discloses a preparation method of 4-tert-butyl-2-chloropyridine and 4-tert-butyl-2,6-dichloro-pyridine. 4-tert-butylpyridine is used as a raw material to be reacted with a chlorination reagent at set temperature under the action of a strong base and an additive to obtain the 4-tert-butyl-2-chloropyridine, and the 4-tert-butyl-2-chloropyridine is used as a raw material to be reacted with a chlorination reagent at set temperature under the action of a strong base and an additive to obtain the 4-tert-butyl-2,6-dichloro-pyridine. The route of the invention has the advantages of shortreaction steps, mild conditions and simple operation and is suitable for large-scale preparation of the 4-tert-butyl-2-chloropyridine and the 4-tert-butyl-2,6-dichloro-pyridine.

ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT USING THE SAME

PROBLEM TO BE SOLVED: To provide a compound which has an electron-donating property and is stable in the atmosphere. SOLUTION: The organic compound is represented by general formula [1] (where n represents an integer from 0 to 3 inclusive; R1 and R4 each represent an alkyl group or an aryl group selected from a phenyl group, a naphthyl group, a biphenyl group, a terphenyl group, a phenanthrenyl group, a fluorenyl group, and a fluoranthenyl group; when R1 or R4 is an aryl group, the aryl group may further have an alkyl group; R2 and R3 each represent an alkyl group or an aryl group selected from a phenyl group, a naphthyl group, a biphenyl group, a terphenyl group, a phenanthryl group, a fluorenyl group, and a fluoranthenyl group; when R2 or R3 is an aryl group, the aryl group may further have an alkyl group, a phenyl group, or a naphthyl group; when R1 and R4 are alkyl groups, R2 and R3 are aryl groups; and when R2 and R3 are alkyl groups, R1 and R4 are aryl groups). SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT

Stereo- and Regioselective Alkyne Hydrometallation with Gold(III) Hydrides

The hydroauration of internal and terminal alkynes by gold(III) hydride complexes [(C^N^C)AuH] was found to be mediated by radicals and proceeds by an unexpected binuclear outer-sphere mechanism to cleanly form trans-insertion products. Radical precursors such as azobisisobutyronitrile lead to a drastic rate enhancement. DFT calculations support the proposed radical mechanism, with very low activation barriers, and rule out mononuclear mechanistic alternatives. These alkyne hydroaurations are highly regio- and stereospecific for the formation of Z-vinyl isomers, with Z/E ratios of >99:1 in most cases.

Heteroleptic Ir(III) phosphors with bis-tridentate chelating architecture for high efficiency OLEDs

A bis-tridentate iridium complex represented by a formula (I): where R3 to R8, R21 to R23, R9, R10, X1, X2, and X3 are as defined in the specification.

2-Amino-1,3,5-triazine chemistry: hydrogen-bond networks, Takemoto thiourea catalyst analogs, and olfactory mapping of a sweet-smelling triazine

Abstract The chemistry of 4,6-dialkyl-2-amino-1,3,5-triazines with bulky alkyl substituents was investigated and their use as building blocks for preparing chiral thiourea organocatalysts explored. Reaction of ammonia with 4,6-di-tert-butyl-2-chloro-1,3,5-triazine gave 4,6-di-tert-butyl-1,3,5-triazin-2-amine which formed extended hydrogen-bond networks in the solid state according to X-ray crystallography. Selected heterocyclic amines were converted to isothiocyanates, and the latter reacted with (S,S)-2-(dimethylamino)cyclohexylamine to give enantiopure 1-hetaryl-3-[2-(dimethylamino)cyclohexyl]thioureas, with hetaryl representing either 4,6-dimethyl-1,3-diazin-2-yl, 4,6-diisopropyl-1,3,5-triazin-2-yl, or 4,6-di-tert-butyl-1,3,5-triazin-2-yl groups. These compounds are structural analogs of Takemotos's chiral thiourea organocatalysts (1-[3,5-bis(trifluoromethyl)phenyl]-3-[(1S,2S)-2-(dimethylamino)cyclohexyl]thiourea) with an aza-aryl instead of the 3,5-bis(trifluoromethyl)phenyl group. They feature a strong intramolecular N-H to N-1 hydrogen bond, as shown by X-ray crystallography of 1-(4,6-di-tert-butyl-1,3,5-triazin-2-yl)-3-[2-(dimethylamino)cyclohexyl]thiourea in the solid state and by 1H NMR spectroscopy of all derivatives in CDCl3 solution, which prevents them from acting as bifunctional organocatalyst. In the reaction of 4,6-di-tert-butyl-2-chloro-1,3,5-triazine with ammonia, 4,6-di-tert-butyl-2-ethoxy-1,3,5-triazine was identified as side-product displaying a mildly sweet, floral odor that is unusual for a 1,3,5-triazine. Analogs (>35) of 4,6-di-tert-butyl-2-ethoxy-1,3,5-triazine were prepared to define the important structural factors of the olfactophore.

Substituted 2,2′-bipyridines by nickel catalysis: 4,4′-Di- tert -butyl-2,2′-bipyridine

A simple, ligand-free synthesis of the important bipyridyl ligand 4,4′-di-tert-butyl-2,2′-bipyridine is presented. 5,5′-Bis(trifluoromethyl)-2,2′-bipyridine is also synthesized by the same protocol. The syntheses efficiently couple the parent 2-chloropyridines by a nickel-catalyzed dimerization with manganese powder as the terminal reductant. Georg Thieme Verlag Stuttgart New York.

PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.

Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.